ReviewInternational ophthalmology2025
Advances in the management of uveitic cataract: current strategies and emerging perspectives.
Review in International ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis review aims to summarize the current knowledge concerning the management of cataract in patients with uveitis.
methodsA meticulous literature search was performed in the PubMed database. A supplementary search was made in Google Scholar to complete the collected items. Studies published up to the end of 2024 were included based on their relevance. To ensure a comprehensive review process, we carried out a critical appraisal evaluating study design, methodology, sample size, and potential bias. Studies that did not provide apposite information or lacked methodological rigor were excluded.
resultsCataract is one of the most frequent complications in patients with uveitis and requires a detailed management to achieve good anatomical and functional outcomes. Comprehensive assessment, patient selection, and preoperative counselling are mandatory, while inflammation must be in remission for at least 3 months before surgery. Since even mild chronic inflammatory activity can contribute to the cumulative damage associated with uveitis, perioperative anti-inflammatory treatment is crucial. Surgery for uveitic patients is made more difficult by a number of factors (such as poorly dilating pupils), but better results can be achieved with advanced surgical methods, careful postoperative monitoring, and timely management of complications. Moreover, the implication of steroid-sparing agents is also very useful in the optimal long-term control of the inflammation.
conclusionsCataract surgery in patients with uveitis can be highly challenging. The ophthalmic surgeon must conduct a thorough preoperative assessment, develop a strategic plan for potential intraoperative challenges, and be prepared to manage possible postoperative complications. Recent advances including artificial intelligence, robotic surgery, next-generation intraocular lenses and novel drugs are expected to enhance the management of cataract in uveitic eyes.
Indexed as
Identifiers
40839288What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.